Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the Future Use of Abbott's Freestyle Libre CGMs in Diabetes Care Amid Safety and Sensor Concerns

Ticker(s): ABT

Who's the expert?

Institution: Stanford

Professor of Endocrinology at Stanford
Manages hundreds of patients for obesity and type 2 diabetes
Research interest in the role of incretin hormones in glucose metabolism and postbariatric hypoglycemia and the use of continuous glucose monitoring

Interview Questions

Q1.

How many patients do you provide with CGM?

Added By: lilly_admin

Q2.

On a scale of 1 to 10, how concerned are you for the FreeStyle Libre 3 & Libre 3 Plus Sensor Correction?

Added By: lilly_admin

Q3.

How many of your type 1 and 2 diabetic patients utilize a CGM?

Added By: ben_admin

Q4.

What are common issues with CGM technologies?

Added By: ben_admin

Q5.

What are your thoughts on the recent sensor issues with the FreeStyle Libre?

Added By: ben_admin

Q6.

Will Abbott lose market share because of these sensor issues?

Added By: ben_admin

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.